$SABS

$2.79 -$0.05 (1.76%) Close

$SABS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 91.0M shares outstanding

Who owns SABS?

By type of holder

Institutions 74.7% Insiders 24.6% Everyone else 0.7%

Concentration Top 10 holders own 83.3%

Vivo Capital, LLC 8.0% · Moin Andrew 12.5%

Institutional ownership

74.7%

-1.4 pts vs last qtr

Institutional holders

+10 vs last qtr

Net shares bought

−1.2M

by institutions in Q2 2026

New / sold out

31 / 21

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Adage Capital Partners GP, L.L.C. +3.0M
BlackRock, Inc. +2.8M

Biggest sellers in Q2 2026

Vivo Capital, LLC −4.1M
Woodline Partners LP −1.7M

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for SAB Biotherapeutics, Inc. in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2024–FY2025

+562.3%

+562.28% a year

Each share's claim on the business

−84.9%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $8.15M

over 2 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years16% Under 1 year84%

Quarterly turnover

18.8%

of institutional shares changed hands

Top 10 managers, median time held

3 quarters

Super Investors

Investment managers reporting SABS on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
VC Vivo Capital, LLC	7.3M	8.02%	−4.1M (−36.1%)	Q3 '25	2.6%
Shares held by quarter Peak holding11.4M (Q3'25) Change over 8 quarters+7.3M Share of the company8.020% Vivo Capital, LLC's full portfolio →
CP Caligan Partners LP	8.0M	8.76%	Unchanged	Q1 '26	1.5%
Shares held by quarter Peak holding8.0M (Q1'26) Change over 8 quarters+8.0M Share of the company8.760% Caligan Partners LP's full portfolio →

Vivo Capital, LLC

7.3M

% of company

8.02%

Change vs last qtr

−4.1M (−36.1%)

Held since

Q3 '25

Caligan Partners LP

8.0M

% of company

8.76%

Change vs last qtr

Unchanged

Held since

Q1 '26

28 more super investors behind a free account

See every manager holding SAB Biotherapeutics, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting SABS on Form N-PORT; together they hold 6.9% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$8.81M	2.3M	2.48%	0.00%	June 30, 2026
IR iShares Russell 2000 ETF iShares Trust	$4.11M	1.1M	1.16%	0.00%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$8.81M

% of company

2.48%

% of the fund

0.00%

As of

June 30, 2026

iShares Russell 2000 ETF

iShares Trust

Position value

$4.11M

% of company

1.16%

% of the fund

0.00%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding SAB Biotherapeutics, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
MA Moin Andrew Insider	11.4M	12.50%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company12.500% Moin Andrew's insider activity →
PK Peter Kolchinsky 5%+ holder 13D · 9.9%	9.6M	10.56%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company10.560% Disclosed stake13D · 9.9% View the 13D/G filing →

Moin Andrew

Insider

11.4M

% of company

12.50%

Change vs last qtr

—

Held since

—

Peter Kolchinsky

5%+ holder13D · 9.9%

9.6M

% of company

10.56%

Change vs last qtr

—

Held since

—

3 more holders behind a free account

See every insider and 5%+ holder of SAB Biotherapeutics, Inc..

Comments